VRTX Vertex Pharmaceuticals
Health Care · Biotechnology · close $499.74 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Vertex Pharmaceuticals (VRTX) has a ThetaGrade House Rating of 62/100 (grade A), ranking #5 of 150 in Health Care. Its strongest pillars are balance sheet (81) and profitability (71); its weakest is analyst sentiment (17). TTM revenue growth is 10.2% and operating margin 38.0%.
Data as of .
Analyst sentiment
weight 7.5% · 17| Consensus score (1–5) (3.8%) | derived | 66 |
| 90-day net rating shift (3.8%) | derived | 0 |
Growth
weight 30.83% · 61| Revenue growth YoY (TTM) (12.3%) | 10.2% | 53 |
| EPS growth YoY (TTM) (12.3%) | 21.7% | 60 |
| Revenue acceleration (6.2%) | 4.6% | 80 |
Profitability
weight 18.5% · 71| Operating margin (9.9%) | 38.0% | 96 |
| 4Q gross-margin change (8.6%) | -0.1% | 43 |
Balance sheet
weight 18.5% · 81| Net debt / EBITDA (9.9%) | -1.21× | 85 |
| Current ratio (4.9%) | 3.19 | 62 |
| Interest coverage (3.7%) | 359.18× | 98 |
Cash flow
weight 12.33% · 68| FCF margin (6.2%) | 26.6% | 88 |
| FCF yield (6.2%) | 2.5% | 48 |
Valuation
weight 12.33% · 41| P/E (inverted) (6.2%) | 29.11× | 55 |
| EV/Sales (inverted) (6.2%) | 9.58× | 26 |
Technicals (EOD)
| RSI(14) | 43.8 |
| EMA 9 / 21 | 503.21 / 508.93 |
| 200-day SMA | 475.90 |
| Volume vs 20d avg | 1.16× |
| 20-day return | -3.2% |
Exit-rule monitor
- WATCHAnalyst drift: net bullish ratings down ≥2 over ~90 days
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like VRTX's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is VRTX's House Rating?
- VRTX scores 62 out of 100 (grade A) as of 2026-10-16, ranking #5 of 150 Health Care stocks we cover.
- What do analysts say about VRTX?
- ThetaGrade's analyst-sentiment pillar for VRTX scores 17/100 against its sector peers, which we read as negative. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does VRTX report earnings next?
- VRTX's next earnings report is estimated for about 2026-11-02 (window 2026-10-30 to 2026-11-05), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is VRTX a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology